Department of Endocrinology, Austin Health, Melbourne, Australia
Division of Endocrinology, Diabetes and Metabolism, Northwell, Great Neck, New York, USA
Search for other papers by Yee-Ming M Cheung in
Google Scholar
PubMed
Search for other papers by Rudolf Hoermann in
Google Scholar
PubMed
Search for other papers by Karen Van in
Google Scholar
PubMed
Search for other papers by Damian Wu in
Google Scholar
PubMed
Search for other papers by Jenny Healy in
Google Scholar
PubMed
Search for other papers by Bella Halim in
Google Scholar
PubMed
Search for other papers by Manjri Raval in
Google Scholar
PubMed
Search for other papers by Maria McGill in
Google Scholar
PubMed
Department of Cardiology, Austin Health, Melbourne Australia
Search for other papers by Ali Al-Fiadh in
Google Scholar
PubMed
Search for other papers by Michael Chao in
Google Scholar
PubMed
Search for other papers by Shane White in
Google Scholar
PubMed
Olivia Newton-John Cancer Research Institute, Austin Health, Melbourne, Australia
Search for other papers by Belinda Yeo in
Google Scholar
PubMed
Department of Endocrinology, Austin Health, Melbourne, Australia
Search for other papers by Jeffrey D Zajac in
Google Scholar
PubMed
Department of Endocrinology, Austin Health, Melbourne, Australia
Search for other papers by Mathis Grossmann in
Google Scholar
PubMed
Introduction In postmenopausal women with early oestrogen receptor-positive (ER+) breast cancer, aromatase inhibitors (AIs) are the mainstay of adjuvant therapy ( 1 ). In this population, AI therapy is directed at the oestrogen axis and
Search for other papers by Masatada Watanabe in
Google Scholar
PubMed
Search for other papers by Shuji Ohno in
Google Scholar
PubMed
Search for other papers by Hiroshi Wachi in
Google Scholar
PubMed
the face of women aged 52–70 years improved their skin thickness (epidermis + dermis) ( 2 ). Oral application of an estrogen-conjugated tablet in postmenopausal women improved skin elasticity, moisture and thickness ( 3 ). Aromatase inhibitors (e
Search for other papers by Enrique Pedernera in
Google Scholar
PubMed
Search for other papers by Flavia Morales-Vásquez in
Google Scholar
PubMed
Search for other papers by María J Gómora in
Google Scholar
PubMed
Search for other papers by Miguel A Almaraz in
Google Scholar
PubMed
Universidad La Salle, Posgrado de la Facultad de Ciencias Químicas, Ciudad de México, México
Search for other papers by Esteban Mena in
Google Scholar
PubMed
Search for other papers by Delia Pérez-Montiel in
Google Scholar
PubMed
Search for other papers by Elizabeth Rendon in
Google Scholar
PubMed
Search for other papers by Horacio López-Basave in
Google Scholar
PubMed
Search for other papers by Juan Maldonado-Cubas in
Google Scholar
PubMed
Search for other papers by Carmen Méndez in
Google Scholar
PubMed
at the tissue level ( 5 , 6 , 7 , 8 ). As for ovarian cancer, intratumoral production of steroid hormones has been suggested ( 9 ), while in ovarian carcinoma, the expression of steroid sulfatase ( 10 ), sulfotransferase ( 11 ), aromatase ( 12
Search for other papers by Teresa Vilariño-García in
Google Scholar
PubMed
Search for other papers by Antonio Pérez-Pérez in
Google Scholar
PubMed
Search for other papers by Esther Santamaría-López in
Google Scholar
PubMed
Search for other papers by Nicolás Prados in
Google Scholar
PubMed
Search for other papers by Manuel Fernández-Sánchez in
Google Scholar
PubMed
Search for other papers by Víctor Sánchez-Margalet in
Google Scholar
PubMed
leptin treatment in GCs from PCOS women ( Fig. 5B ), suggesting that some factors aberrantly expressed in PCOS could be inhibiting the leptin signal transduction pathways. Figure 5 Effect of leptin on aromatase mRNA expression and diminished
West Cancer Center, Memphis, Tennessee, USA
Search for other papers by Michael Ulm in
Google Scholar
PubMed
Search for other papers by Arvind V Ramesh in
Google Scholar
PubMed
Search for other papers by Keely M McNamara in
Google Scholar
PubMed
Search for other papers by Suriyan Ponnusamy in
Google Scholar
PubMed
Search for other papers by Hironobu Sasano in
Google Scholar
PubMed
West Cancer Center, Memphis, Tennessee, USA
Search for other papers by Ramesh Narayanan in
Google Scholar
PubMed
signaling. Two classes of drugs are available, with one directly antagonizing or degrading the ER in breast cancer cells and the other inhibiting the enzyme aromatase, which is important for the synthesis of estradiol, the primary circulating estrogen, from
Search for other papers by Xi Wang in
Google Scholar
PubMed
Search for other papers by Qi Yu in
Google Scholar
PubMed
, and the benefits of current interventions have not been well-established due to the rarity of patients and the heterogeneous nature of the disease. Aromatase inhibitors, which were originally developed for the treatment of oestrogen receptor
Search for other papers by Chan Sub Park in
Google Scholar
PubMed
Search for other papers by Jihye Choi in
Google Scholar
PubMed
Search for other papers by Min-Ki Seong in
Google Scholar
PubMed
Search for other papers by Sung-Eun Hong in
Google Scholar
PubMed
Search for other papers by Jae-Sung Kim in
Google Scholar
PubMed
Search for other papers by In-Chul Park in
Google Scholar
PubMed
Search for other papers by Hyesil Seol in
Google Scholar
PubMed
Search for other papers by Woo Chul Noh in
Google Scholar
PubMed
Search for other papers by Hyun-Ah Kim in
Google Scholar
PubMed
obesity on the prognosis of breast cancer is magnified in menopausal women and those with suppressed ovarian function. Importantly, the prognosis of menopausal patients with breast cancer is affected by obesity; this might arise from elevated aromatase in
Search for other papers by Iben Katinka Greiber in
Google Scholar
PubMed
Search for other papers by Casper P Hagen in
Google Scholar
PubMed
Search for other papers by Alexander Siegfried Busch in
Google Scholar
PubMed
Search for other papers by Mikkel Grunnet Mieritz in
Google Scholar
PubMed
Search for other papers by Lise Aksglæde in
Google Scholar
PubMed
Search for other papers by Katharina Main in
Google Scholar
PubMed
Search for other papers by Kristian Almstrup in
Google Scholar
PubMed
Search for other papers by Anders Juul in
Google Scholar
PubMed
-Müllerian hormone produces endocrine sex reversal of fetal ovaries . PNAS 1989 86 3684 – 3688 . ( https://doi.org/10.1073/pnas.86.10.3684 ) 17 Grossman MP Nakajima ST Fallat ME Siow Y. Müllerian-inhibiting substance inhibits cytochrome p450 aromatase
Search for other papers by Martin Zweifel in
Google Scholar
PubMed
Search for other papers by Beat Thürlimann in
Google Scholar
PubMed
Search for other papers by Salome Riniker in
Google Scholar
PubMed
Search for other papers by Patrik Weder in
Google Scholar
PubMed
Search for other papers by Roger von Moos in
Google Scholar
PubMed
Search for other papers by Olivia Pagani in
Google Scholar
PubMed
Search for other papers by Martin Bigler in
Google Scholar
PubMed
Search for other papers by Karin M Rothgiesser in
Google Scholar
PubMed
Search for other papers by Christiane Pilop in
Google Scholar
PubMed
Search for other papers by Hanne Hawle in
Google Scholar
PubMed
Search for other papers by Peter Brauchli in
Google Scholar
PubMed
Search for other papers by Coya Tapia in
Google Scholar
PubMed
Search for other papers by Wolfgang Schoenfeld in
Google Scholar
PubMed
Search for other papers by Cristiana Sessa in
Google Scholar
PubMed
Search for other papers by for the Swiss Group for Clinical Cancer Research (SAKK) in
Google Scholar
PubMed
androgen receptor (AR) modulators (SARMs) rather than testosterone may be used to treat AR-positive BC. CR1447 (4-hydroxytestosterone (4-OHT)) is a steroidal small molecule with two distinct properties, acting as a steroidal aromatase inhibitor (AI) and
Search for other papers by Kristin Ottarsdottir in
Google Scholar
PubMed
Department of Endocrinology, Sahlgrenska University Hospital, Gothenburg, Sweden
Search for other papers by Anna G Nilsson in
Google Scholar
PubMed
Search for other papers by Margareta Hellgren in
Google Scholar
PubMed
Search for other papers by Ulf Lindblad in
Google Scholar
PubMed
Search for other papers by Bledar Daka in
Google Scholar
PubMed
cytokines, leptin, estradiol and insulin. These substances may inhibit the activity of the hypothalamic–pituitary gonadal axis at multiple levels, thus lowering the concentrations of testosterone ( 7 ). There is also evidence that obesity increases aromatase